The Gross Margin of Coherus Oncology Inc (CHRS) is
67.24%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
67.24%
|
| 2024-12-31 |
96.73%
|
| 2023-12-31 |
38.19%
|
| 2022-12-31 |
66.78%
|
| 2021-12-31 |
82.36%
|
| 2020-12-31 |
92.08%
|
| 2019-12-31 |
95.20%
|
| Ticker |
Name |
Value |
|
STRO
|
Sutro Biopharma Inc
|
7775.20%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
MGNX
|
MacroGenics Inc
|
75.91%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
HRBR
|
Harbor Diversified Inc
|
55.68%
|
|
XENE
|
Xenon Pharmaceuticals Inc.
|
7775.20%
|
|
ANIK
|
Anika Therapeutics Inc
|
56.56%
|
|
CDMO
|
Avid Bioservices Inc
|
5.23%
|
|
ESPR
|
Esperion Therapeutics, Inc.
|
67.95%
|
|
AKBA
|
Akebia Therapeutics Inc
|
82.91%
|
|
HRTX
|
Heron Therapeutics Inc
|
73.31%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
ADMS
|
Adamas Pharmaceuticals Inc
|
97.26%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
MNKD
|
MannKind Corporation
|
77.77%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
75.62%
|
|
MDXG
|
MiMedx Group, Inc.
|
82.56%
|
|
MYGN
|
Myriad Genetics, Inc.
|
69.93%
|
|
SVA
|
Sinovac Biotech Ltd
|
59.51%
|
|
TVTX
|
Travere Therapeutics, Inc.
|
97.89%
|
|
AMRN
|
Amarin Corporation PLC
|
56.57%
|
|
CPRX
|
Catalyst Pharmaceuticals, Inc.
|
85.19%
|
|
CRIS
|
Curis Inc
|
99.52%
|
|
ICPT
|
Intercept Pharmaceuticals Inc
|
99.66%
|
|
PGEN
|
Precigen, Inc.
|
50.20%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
ATNX
|
Athenex Inc
|
25.97%
|
|
EGRX
|
Eagle Pharmaceuticals Inc
|
70.03%
|
|
ENTA
|
Enanta Pharmaceuticals Inc
|
100.00%
|
|
FLXN
|
Flexion Therapeutics Inc
|
77.50%
|
|
LXRX
|
Lexicon Pharmaceuticals, Inc.
|
99.45%
|
|
TH.TO
|
Theratechnologies Inc
|
76.19%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
CLDX
|
Celldex Therapeutics, Inc.
|
100.00%
|